Skip to main content

Table 3 Clinical trials aiming to cancer treatment using MSCs

From: Mesenchymal stem cells and cancer therapy: insights into targeting the tumour vasculature

Cancer type Trial NCT number Treatment approach Phase Country Status Year
Hematological malignancies NCT01045382 MSC II Belgium Recruiting 2010
Hematological malignancies NCT01092026 Umbilical cord blood hematopoietic stem cell (UCB-HSC) transplantation with co-infusion of MSCs I, II Belgium Unknown 2010
Myelodysplastic syndromes NCT01129739 MSCs derived from human umbilical cord/placenta II China Unknown 2010
Solid tumors metastases NCT01844661 Bone marrow-derived autologous MSCs infected with ICOVIR5 (Celyvir) I, II Spain Completed 2013
Prostate cancer NCT01983709 Bone marrow-derived MSCs I US Terminated (Study was Terminated by PI due to low accrual) 2013
Hematological malignancies NCT02270307 Cyclophosphamide and MSC II, III Russia Unknown 2014
Ovarian cancer NCT02068794 Tissue-derived MSCs infected with oncolytic measles virus encoding thyroidal sodium iodide symporter (AdMSC-MV-NIS) I, II US Recruiting 2014
Hematological malignancies NCT02181478 Intra-osseous umbilical cord blood hematopoietic stem cells (UC-HSC) and MSC I US Completed 2015
Ovarian cancer NCT02530047 Bone marrow-derived MSCs expressing INF-β (BM-MSC-β) I US Completed 2016
Myelodysplastic syndromes NCT03184935 Human umbilical cord-derived MSCs I, II China Suspended 2017
Lung adenocarcinoma NCT03298763 MSCs genetically engineered to express TRAIL (MSC-TRAIL) I, II UK Recruiting 2019
Pancreatic cancer NCT03608631 MSC-derived exosomes loaded with KrasG12D siRNA I US Not yet recruiting 2019
Glioma NCT03896568 Allogeneic bone marrow-derived MSCs loaded with the oncolytic adenovirus DNX-2401 (BM-MSCs-DNX2401 I US Recruiting 2019